Literature DB >> 10577977

Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7.

J Kempeni1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10577977      PMCID： PMC1766582          DOI： 10.1136/ard.58.2008.i70

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  11 in total

1.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

Authors:  L W Moreland; S W Baumgartner; M H Schiff; E A Tindall; R M Fleischmann; A L Weaver; R E Ettlinger; S Cohen; W J Koopman; K Mohler; M B Widmer; C M Blosch
Journal:  N Engl J Med       Date:  1997-07-17       Impact factor: 91.245

Review 2.  Clinical management of rheumatoid arthritis.

Authors:  P M Brooks
Journal:  Lancet       Date:  1993-01-30       Impact factor: 79.321

Review 3.  Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis.

Authors:  A F Kavanaugh
Journal:  Rheum Dis Clin North Am       Date:  1998-08       Impact factor: 2.670

4.  Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions.

Authors:  B J Scallon; M A Moore; H Trinh; D M Knight; J Ghrayeb
Journal:  Cytokine       Date:  1995-04       Impact factor: 3.861

Review 5.  TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.

Authors:  R N Maini; F M Brennan; R Williams; C Q Chu; A P Cope; D Gibbons; M Elliott; M Feldmann
Journal:  Clin Exp Rheumatol       Date:  1993 Mar-Apr       Impact factor: 4.473

6.  Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Authors:  M J Elliott; R N Maini; M Feldmann; A Long-Fox; P Charles; P Katsikis; F M Brennan; J Walker; H Bijl; J Ghrayeb
Journal:  Arthritis Rheum       Date:  1993-12

7.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.

Authors:  A M van Gestel; M L Prevoo; M A van 't Hof; M H van Rijswijk; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1996-01

8.  The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.

Authors:  E C Rankin; E H Choy; D Kassimos; G H Kingsley; A M Sopwith; D A Isenberg; G S Panayi
Journal:  Br J Rheumatol       Date:  1995-04

9.  Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen.

Authors:  L S Jespers; A Roberts; S M Mahler; G Winter; H R Hoogenboom
Journal:  Biotechnology (N Y)       Date:  1994-09

10.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

Authors:  J Keffer; L Probert; H Cazlaris; S Georgopoulos; E Kaslaris; D Kioussis; G Kollias
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598
View more
  28 in total

1.  Building towards a consensus for the use of tumour necrosis factor blocking agents.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen
Journal:  Ann Rheum Dis       Date:  1999-12       Impact factor: 19.103

Review 2.  Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody.

Authors:  J Kempeni
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

3.  Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade.

Authors:  Julia Kleinert; Matthias Lorenz; Wolfgang Köstler; Walter Hörl; Gere Sunder-Plassmann; Afschin Soleiman
Journal:  Wien Klin Wochenschr       Date:  2004-05-31       Impact factor: 1.704

4.  Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect.

Authors:  R F van Vollenhoven; S Brannemark; L Klareskog
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

Review 5.  Analysing the effect of novel therapies on cytokine expression in experimental arthritis.

Authors:  Richard O Williams; Julia J Inglis; Egle Simelyte; Gabriel Criado; Percy F Sumariwalla
Journal:  Int J Exp Pathol       Date:  2005-10       Impact factor: 1.925

6.  A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNFα monoclonal antibody with biosimilar potential.

Authors:  Mateus Dalcin Luchese; Mariana Lopes Dos Santos; Angelica Garbuio; Roselaine Campos Targino; Carla Ploeger Mansueli; Lilian Rumi Tsuruta; Wagner Quintilio; Ana Maria Moro
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

7.  Tumor necrosis factor alpha -308 polymorphism is associated with rheumatoid arthritis in Han population of Eastern China.

Authors:  Ruiwen Chen; Meng Fang; Qing Cai; Shiwei Duan; Ke Lv; Ning Cheng; Daming Ren; Jie Shen; Dongyi He; Lin He; Shuhan Sun
Journal:  Rheumatol Int       Date:  2007-08-21       Impact factor: 2.631

Review 8.  Medical management of crohn disease.

Authors:  Frank I Scott; Mark T Osterman
Journal:  Clin Colon Rectal Surg       Date:  2013-06

Review 9.  [Systemic psoriasis therapy - the next step. Adalimumab].

Authors:  G Wozel; M Sticherling
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

10.  Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature.

Authors:  Jochen Schmitt; Gottfried Wozel
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.